Naina Mohamed Maideen

Dr. Naina Mohamed Maideen

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Chonnam Medical Journal
Verified
Journal Article
Open access
PDF file
NMNaina Mohamed Maideen
Naina Mohamed Maideen
Maideen NM. Chonnam Med J. 2023 May;59(2):115-127. https://doi.org/10.4068/cmj.2023.59.2.115

14 July 2021 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
RBRajkapoor Balasubramaniam
Rajkapoor Balasubramaniam
NMNaina Mohamed Maideen
Naina Mohamed Maideen
Background: Hydroxymethyl glutaryl-CoA (HMG-CoA) reductase inhibitors (Statins) are used to treat dyslipidemia. Generally, the statins are the substrates of CYP enzymes, P-glycoprotein (P-gp), and organic anion transporting polypeptides transporters (OATP1B1). Objective: This review article focuses on the clinical significance of statins, and their interactions in real practice. Method: The databases like Medline/PubMed Central/PubMed, Google Scholar, Science Direct, Cochrane Library, Directory of open access journals (DOAJ), and reference lists were searched to identify relevant articles. Results: Most of the drug interactions of statins result in elevated plasma concentrations and toxicity of statins due to the inhibition of CYP3A4, P-gp and/or OATP1B1 transporters. The toxicity of statins includes myopathy, rhabdomyolysis, elevated liver enzymes, acute kidney injury, and diabetes. The statins like Simvastatin, Lovastatin, and Atorvastatin are substrates of CYP3A4 enzyme and P-glycoprotein and their concomitant use with the drugs inhibiting or inducing them would result in changes in plasma concentrations and toxicity/efficacy. However, the statins like Pravastatin, Rosuvastatin and Pitavastatin are not substrates of CYP enzymes and hence the concomitant use of CYP inhibitors or inducers do not affect them. Almost all the statins are the substrates of OATP1B1 transporter, and the co-prescription of inhibitors of OATP1B1 elevates the plasma concentrations and muscle toxicity of statins. Conclusion: Understanding the interacting potential of each statin will enable the prescribers, pharmacists, and other health care professionals to use statins effectively without compromising patient safety.

30 June 2020 in Journal of Pharmacopuncture
Verified
Journal Article
Open access
PDF file
NMNaina Mohamed Maideen
Naina Mohamed Maideen
Naina Mohamed Pakkir Maideen. J Pharmacopuncture 2020;23:62-70. https://doi.org/10.3831/KPI.2020.23.010

1 January 2021 in Chonnam Medical Journal
Verified
Journal Article
Open access
PDF file
NMNaina Mohamed Maideen
Naina Mohamed Maideen
Maideen NM. Chonnam Med J. 2021 Sep;57(3):169-175. https://doi.org/10.4068/cmj.2021.57.3.169

31 December 2017 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
NMNaina Mohamed Maideen
Naina Mohamed Maideen
AJAbdurazak Jumale
Abdurazak Jumale
RBRajkapoor Balasubramaniam
Rajkapoor Balasubramaniam
Metformin is a most widely used medication all around the world to treat Type 2 diabetes mellitus. It is also found to be effective against various conditions including, Prediabetes, Gestational diabetes mellitus (GDM), Polycystic Ovarian Syndrome (PCOS), Obesity, Cancer, etc. It is a cationic drug and it depends Organic Cation Transporters (OCTs) and Multidrug and Toxin Extruders (MATEs) mostly for its pharmacokinetics movement. The probability of drug interaction increases with the number of concomitant medications. This article focuses the drug interactions of metformin and most of them are linked to the inhibition of OCTs and MATEs leading to increased plasma metformin concentrations and subsequent elevation of risk of Metformin Associated Lactic Acidosis (MALA). By identifying the drugs inhibiting OCTs and MATEs, the healthcare professionals can predict the drug interactions of metformin.

30 January 2019 in World Journal of Pharmacology
Verified
Journal Article
Open access
NMNaina Mohamed Maideen
Naina Mohamed Maideen
Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine